Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Oncology in Practice
  3. Palliative and Supportive care
  4. Multikinase Inhibitor-Related Skin Toxicity
  5. Healthcare Professionals

Prophylaxis and Treatment

Previous Page Next Page

Overview of prophylaxis and treatment of multikinase inhibitor-induced dermatologic side effects

The dermatologic side effects associated with multikinase inhibitor treatment are addressed on this website. This section of the website, ‘Prophylaxis and treatment’, comprises the following sub-sections:

  • What healthcare providers should know and what patients can do: Healthcare providers (HCPs) should know the key treatment principles for multikinase inhibitor-related skin toxicities and the key behavioural and prophylactic measures that can be undertaken by patients to minimise dermatologic side effects
  • Flexible dosing strategies: What healthcare professionals should do to treat side effects of multikinase inhibitor treatment
  • Prophylactic management: Therapeutic principles, which help to minimise the grade and extent of toxicities
  • Reactive management: Information on close monitoring of and early intervention in dermatologic side effects associated with multikinase inhibitors

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.